Atria Investments Inc Lowers Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Atria Investments Inc decreased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 10.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 36,234 shares of the medical equipment provider’s stock after selling 4,254 shares during the period. Atria Investments Inc’s holdings in Intuitive Surgical were worth $17,800,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Mirador Capital Partners LP boosted its holdings in shares of Intuitive Surgical by 1.4% in the third quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider’s stock valued at $1,732,000 after purchasing an additional 50 shares during the period. Advisors Asset Management Inc. raised its stake in Intuitive Surgical by 18.1% in the first quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock worth $2,945,000 after buying an additional 1,129 shares in the last quarter. Consolidated Planning Corp raised its stake in Intuitive Surgical by 17.4% in the third quarter. Consolidated Planning Corp now owns 8,099 shares of the medical equipment provider’s stock worth $3,979,000 after buying an additional 1,198 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its stake in Intuitive Surgical by 617.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider’s stock worth $39,622,000 after buying an additional 76,649 shares in the last quarter. Finally, Brookstone Capital Management raised its stake in Intuitive Surgical by 22.4% in the second quarter. Brookstone Capital Management now owns 12,530 shares of the medical equipment provider’s stock worth $5,340,000 after buying an additional 2,289 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

NASDAQ:ISRG opened at $536.45 on Friday. Intuitive Surgical, Inc. has a one year low of $269.49 and a one year high of $538.49. The firm has a market cap of $191.07 billion, a price-to-earnings ratio of 86.25, a PEG ratio of 5.07 and a beta of 1.39. The firm’s fifty day moving average is $493.92 and its two-hundred day moving average is $451.73.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating the consensus estimate of $1.24 by $0.32. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. The company had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.01 billion. As a group, equities research analysts predict that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 240 shares of the company’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $464.76, for a total value of $111,542.40. Following the sale, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at approximately $2,558,968.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Robert Desantis sold 240 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $464.76, for a total transaction of $111,542.40. Following the sale, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,558,968.56. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel Gary Loeb sold 300 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $475.00, for a total transaction of $142,500.00. Following the sale, the general counsel now directly owns 1,595 shares in the company, valued at approximately $757,625. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 68,246 shares of company stock valued at $33,839,308. 0.90% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts recently commented on ISRG shares. Oppenheimer reissued a “market perform” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. JPMorgan Chase & Co. boosted their price objective on shares of Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Stifel Nicolaus boosted their price objective on shares of Intuitive Surgical from $475.00 to $525.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Mizuho upped their price target on Intuitive Surgical from $440.00 to $500.00 in a research report on Thursday, October 17th. Finally, Redburn Atlantic raised Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their price target for the stock from $380.00 to $510.00 in a research report on Friday, August 2nd. One analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $513.74.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.